Can‑Fite Reports Safe Phase 2a Readout and Survival Signals for Namodenoson in Advanced Pancreatic Cancer

Overview

• Can‑Fite said Wednesday that its open‑label Phase 2a trial met the primary safety endpoint after enrolling 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed on standard therapies.
• An updated analysis limited to eight evaluable third‑line patients showed a median overall survival of more than five months, with 62.5% alive at five months and 37.5% alive at seven months, and two patients still living at the data cutoff.
• The study included a standout case in the second‑line group: one patient remained alive more than 18 months after starting Namodenoson, the longest survival reported in the trial.
• Can‑Fite cited a recent peer‑reviewed preclinical paper that found Namodenoson enhances the activity of chemotherapy by blocking proliferation and drug‑resistance pathways, and the company says these data support a planned Phase 2b chemotherapy combination study.
• The findings are preliminary because the trial was small, open‑label and relied on subgroup analyses, and larger controlled studies will be needed to confirm benefit even as the stock jumped about 65% on the announcement.